Does therapy of the primary tumor matter in oligometastatic prostate cancer? A prospective 10-year follow-up study
Authors Poulsen MH, Jakobsen JS, Mortensen MA, Høilund-Carlsen PF, Lund L
Received 8 October 2018
Accepted for publication 15 April 2019
Published 30 July 2019 Volume 2019:11 Pages 215—221
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Jan Colli
Mads Hvid Poulsen,1,2 Jørn Skibsted Jakobsen,3 Mike Allan Mortensen,1,4 Poul Flemming Høilund-Carlsen,4,5 Lars Lund1,2,4
1Department of Urology, Odense University Hospital, Odense, Denmark; 2Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark; 3Department of Urology, Herlev and Gentofte University Hospital, Copenhagen, Denmark; 4Department of Clinical Research, University of Southern Denmark, Odense, Denmark; 5Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark
Objective: The effect of curative treatment for oligometastatic prostate cancer patients is unsolved, both with regard to morbidity and mortality. With this study, we provide some of the first long-term follow-up data on progression and mortality in oligometastatic prostate cancer patients after curative treatment of their primary tumor.
Methods: A cohort of 210 patients with diagnosed prostate cancer was established between 2008 and 2010. All patients were scheduled for intended curative treatment, and all underwent blinded 18F-choline positron-emission tomography/computed tomography at inclusion prior to curative treatment. Upon unblinding, 12 patients (6%) were recategorized as being oligometastatic. They had a mean age of 64 years,median prostate-specific antigen of 18 ng/mL, and median Gleason score of 7. Six patients were staged as T3, one T2, and five T1. The patients had a medianof one bone metastasis (range 1–2). All underwent intended curative radiotherapy or prostatectomy. Mean follow-up was 10.1 (8.9–11.0) years.
Results: During follow-up of the 12 patients, three (25%) had biochemical recurrence, two developed castration-resistant disease, and one died due to prostate cancer.
Conclusion: Our results suggest that intended curative treatment of the primary tumor in oligometastatic prostate cancer may have a role in highly selected patients.
Keywords: prostate cancer, oligometastases, treatment
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]